ADVANCED DRUG DEVELOPMENT PLATFORM
PharmaBiota® is our platform for the development of novel biological medicines derived from the microbiota, that has enabled us to develop two product modalities and three biological medicines.
Purified Microbiota Ecosystem
Microviable lead product, MVT-201, represents the complete gut microbiota ecosystem, ultra purified, with high bacterial diversity and full functionality, to be harnessed as a biological medicine.
Microviable has developed a proprietary and patented manufacturing process that enables to obtain this unique product. It is generated through ultra purification without propagation, ensuring high-concentration, high-diversity and high-richness. It is the only product that solely contains the microbial fraction of the microbiota, without fecal components. It has a higher safety profile than other fecal microbiota transplant (FMT) products.
Our lead candidate MVT-201, is an orally administered capsule, generated under GMP conditions with great efficacy results in preclinical models.
Defined bacterial consortia
Leveraging our results with ultra purified complete microbiota ecosystem together with our drug development platform and data analysis, PharmaBiota®, we have developed a novel product category.
We strategically select the bacterial species with higher potential after a bioinformatic screening and in vitro validation in our laboratory, developing defined bacterial consortia that include specific bacterial strains. These are tailored products for each specific diseases or medical indication.
These products are oral capsule, non-donor dependent, with a define composition at the genome level of each strain and are scalable through fermentation, enabling their application in medical conditions with high incidence.
From a regulatory perspective, they are considered biological medicines under the Live Biotherapeutic Products (LBPs) category.
Defined bacterial consortia
Leveraging our results with ultra purified complete microbiota ecosystem together with our drug development platform and data analysis, PharmaBiota®, we have developed a novel product category.
We strategically select the bacterial species with higher potential after a bioinformatic screening and in vitro validation in our laboratory, developing defined bacterial consortia that include specific bacterial strains. These are tailored products for each specific diseases or medical indication.
These products are oral capsule, non-donor dependent, with a define composition at the genome level of each strain and are scalable through fermentation, enabling their application in medical conditions with high incidence.
From a regulatory perspective, they are considered biological medicines under the Live Biotherapeutic Products (LBPs) category.
PharmaBiota® Platform
Our Advance Microbiota Drug Development Platform enables the generation of a novel category of biotherapeutic products based on commensal bacteria developing personalized drugs for unmet clinical needs.
Our large and diverse proprietary bacterial culture collection together with our bioinformatics platform enable the discovery of novel microbiota-derived biological drugs, tailored with our in house characterization pipeline and cGMP production.
| Patent No. | Title | Applicant | Issue date |
|---|---|---|---|
| ES201630176 | Device for microbiota collection and transport in anaerobic condition | CSIC | July 10, 2018 |
| EP19383077 | Tools and methods to detect and isolate colibactin producing bacteria | CSIC | Pending |
| Trade Secret (ref.: 2203) | Methods for long-term preservation of gut microbiota in viable conditions | CSIC-MVT | April 13, 2021 |
| Trade mark | PharmaBiota® | Microviable Therapeutics | December 02, 2022 |
| Trade mark | HiPM® – Human Purified Microbiota | Microviable Therapeutics | June 08, 2022 |
| Trade mark | GutAlive® | Microviable Therapeutics | January 23, 2018 |
| Trade mark | Microviable Therapeutics® | Microviable Therapeutics | April 26, 2017 |
Patent No.: ES201630176
Title: Device for microbiota collection and transport in anaerobic condition
Applicant: CSIC
Issue date: July 10, 2018
Patent No.: EP19383077
Title: Tools and methods to detect and isolate colibactin producing bacteria
Applicant: CSIC
Issue date: Pending
Patent No.: Trade Secret (ref.: 2203)
Title: Methods for long-term preservation of gut microbiota in viable conditions
Applicant:CSIC-MVT
Issue date: April 13, 2021
Patent No.: Trade mark
Title: PharmaBiota®
Applicant: Microviable Therapeutics
Issue date: December 02, 2022
Patent No.: Trade mark
Title: HiPM® – Human Purified Microbiota
Applicant: Microviable Therapeutics
Issue date: June 08, 2022
Patent No.: Trade mark
Title: GutAlive®
Applicant: Microviable Therapeutics
Issue date: January 23, 2018
Patent No.: Trade mark
Title: Microviable Therapeutics®
Applicant: Microviable Therapeutics
Issue date: April 26, 2017
* All the disclosed IP has been licensed with exclusive rights to Microviable Therapeutics SL.